Press "Enter" to skip to content

Vertex posts positive data from cystic fibrosis triple combo trials

The company said the combination regimen, comprising its experimental agent VX-659 and its other CF drugs Kalydeco and tezacaftor, showed a 10 percentage point improvement in lung function in patients compared to those treated with placebo and the other two drugs.

Original source: https://health.economictimes.indiatimes.com/news/pharma/vertex-posts-positive-data-from-cystic-fibrosis-triple-combo-trials/66845808?utm_source=RSS&utm_medium=ETRSS